Beneficial effects of mifepristone treatment in patients with breast cancer selected by the progesterone receptor isoform ratio: results from the MIPRA trial

A Elía, L Saldain, SI Vanzulli, LA Helguero… - Clinical Cancer …, 2023 - AACR
Purpose: Preclinical data suggest that antiprogestins inhibit the growth of luminal breast
carcinomas that express higher levels of progesterone receptor isoform A (PRA) than …
被引用次数：18 相关文章

Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial

A Elía, L Saldain, SI Vanzulli… - … : an official journal …, 2023 - pubmed.ncbi.nlm.nih.gov
Purpose Preclinical data suggest that antiprogestins inhibit the growth of luminal breast
carcinomas that express higher levels of progesterone receptor isoform A (PRA) than …

Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial

AM Elia, L Saldain, S Vanzulli, LA Helguero… - 2022 - notablesdelaciencia.conicet.gov.ar
Purpose: Preclinical data suggest that antiprogestins inhibit the growth of luminal breast
carcinomas that express higher levels of progesterone receptor isoform A (PRA) than …
[HTML] nih.gov

[HTML][HTML] Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial

A Elía, L Saldain, SI Vanzulli, LA Helguero… - Clinical Cancer …, 2023 - ncbi.nlm.nih.gov
Purpose: Preclinical data suggest that antiprogestins inhibit the growth of luminal breast
carcinomas that express higher levels of progesterone receptor isoform A (PRA) than …

Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial

AM Elia, L Saldain, S Vanzulli, LA Helguero… - 2022 - datosdeinvestigacion.conicet.gov.ar
Purpose: Preclinical data suggest that antiprogestins inhibit the growth of luminal breast
carcinomas that express higher levels of progesterone receptor isoform A (PRA) than …

Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial

AM Elia, L Saldain, S Vanzulli, LA Helguero, CA Lamb… - 2022 - ri.conicet.gov.ar
Purpose: Preclinical data suggest that antiprogestins inhibit the growth of luminal breast
carcinomas that express higher levels of progesterone receptor isoform A (PRA) than …

Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial.

A Elía, L Saldain, SI Vanzulli, LA Helguero… - … Cancer Research: an …, 2023 - europepmc.org
Purpose Preclinical data suggest that antiprogestins inhibit the growth of luminal breast
carcinomas that express higher levels of progesterone receptor isoform A (PRA) than …
[PDF] aacrjournals.org

[PDF][PDF] Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial

A Elía, L Saldain, SI Vanzulli, LA Helguero… - Clinical Cancer …, 2023 - AACR
Purpose: Preclinical data suggest that antiprogestins inhibit the growth of luminal breast
carcinomas that express higher levels of progesterone receptor isoform A (PRA) than …

Beneficial effects of mifepristone treatment in breast cancer patients selected by the progesterone receptor isoform ratio: Results from the MIPRA trial.

A Elía, L Saldain, SI Vanzulli, LA Helguero… - … Cancer Research: an …, 2022 - europepmc.org
Purpose Preclinical data suggest that antiprogestins inhibit the growth of luminal breast
carcinomas that express higher levels of progesterone receptor isoform A (PRA) than …